pubmed.ncbi.nlm.nih.gov

The counterfeit anti-malarial is a crime against humanity: a systematic review of the scientific evidence - PubMed

  • ️Wed Jan 01 2014

Review

The counterfeit anti-malarial is a crime against humanity: a systematic review of the scientific evidence

Kaliyaperumal Karunamoorthi. Malar J. 2014.

Abstract

Background: The counterfeiting of anti-malarials represents a form of attack on global public health in which fake and substandard anti-malarials serve as de facto weapons of mass destruction, particularly in resource-constrained endemic settings, where malaria causes nearly 660,000 preventable deaths and threatens millions of lives annually. It has been estimated that fake anti-malarials contribute to nearly 450,000 preventable deaths every year. This crime against humanity is often underestimated or ignored. This study attempts to describe and characterize the direct and indirect effects of counterfeit anti-malarials on public health, clinical care and socio-economic conditions.

Methods: A search was performed using key databases, WHO documents, and English language search engines. Of 262 potential articles that were identified using a fixed set of criteria, a convenience sample of 105 appropriate articles was selected for this review.

Results: Artemisinin-based combination therapy (ACT) is an important tool in the fight against malaria, but a sizable number of patients are unable to afford to this first-line treatment. Consequently, patients tend to procure cheaper anti-malarials, which may be fake or substandard. Forensic palynology reveals that counterfeits originate in Asia. Fragile drug regulations, ineffective law-enforcement agencies and corruption further burden ailing healthcare facilities. Substandard/fake anti-malarials can cause (a) economic sabotage; (b) therapeutic failure; (c) increased risk of the emergence and spread of resistant strains of Plasmodium falciparum and Plasmodium vivax; (d) an undermining of trust/confidence in healthcare stakeholders/systems; and, (e) serious side effects or death.

Conclusion: Combating counterfeit anti-malarials is a complex task due to limited resources and poor techniques for the detection and identification of fake anti-malarials. This situation calls for sustainable, global, scientific research and policy change. Further, responsible stakeholders in combination with the synthesis and supply of next generation malaria control tools, such as low-cost anti-malarials, must promote the development of a counterfeit-free and malaria-free future.

PubMed Disclaimer

Figures

Figure 1
Figure 1

Pharmaceutical crime incidents by region, 2012 (Source: Pharmaceutical Security Institute, 2013)[11].

Figure 2
Figure 2

PRISMA flow diagram showing the exclusion and inclusion of studies for analysis.

Figure 3
Figure 3

Counterfeit Detection Device (CD-3) (Credit: US-FDA, 2013)[60].

Similar articles

Cited by

References

    1. Wertheimer AI, Wang PG. Counterfeit Medicines. Vol. 1. St Albans: ILM Publications; 2012. (Policy, Economics, and Counter Measures).
    1. WHO. Counterfeit Medicines. Fact Sheet. 2006. p. 275. http://www.who.int/mediacentre/factsheets/fs275/en/. Accessed on 15th June 2013.
    1. Redpath S. Trade in illegal medicine hits pharmaceutical sector, in World Finance 20 April 2012, World News Media. 2012. Online.
    1. Pitts P. Counterfeit drug sales to reach $75 billion by 2010, report say. Heartland Institute; November 2005. http://www.heartland.org/publications/health%20care/article/17948/Counte.... Accessed on 06th May 2013.
    1. WHPA. Background Document on Counterfeit Medicines in Asia. (WHPA Regional Workshop on Counterfeit Medical Products, Taipei, Taiwan 30th June– 1st July 2011). http://www.whpa.org/Background_document_Counterfeit_Medicines_in_Asia.pdf. Accessed on 12th June 2014.

Publication types

MeSH terms

Substances